Author： Nechansky Andreas Kircheis Ralf
Publisher： Informa Healthcare
ISSN： 1746-0441
Source： Expert Opinion on Drug Discovery, Vol.5, Iss.11, 2010-11, pp. : 1067-1079
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Minimizing the immunogenicity of protein therapeutics
By Chirino A.J. Ary M.L. Marshall S.A.
Drug Discovery Today, Vol. 9, Iss. 2, 2004-01 ,pp. :
Access to resources
Recommend
Reducing the Immunogenicity of Protein Therapeutics
Current Drug Targets, Vol. 10, Iss. 2, 2009-02 ,pp. :
RIX 4414 shows safety and immunogenicity in infants
Inpharma, Vol. 1, Iss. 1664, 2008-01 ,pp. :
Efficacy and safety of trastuzumab
Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. :
The safety and efficacy of antithyroid drugs
Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. :